Regulatory environment

A series of landmark legislative and regulatory reforms has transformed the legal and regulatory landscape for paediatric clinical trials over the past two decades, driven by recognition that children were systematically underrepresented in drug development programmes. Understanding the regulatory environment is essential for trial designers, since the requirements differ significantly between jurisdictions and failure to comply can result in significant delays or the inability to obtain marketing authorization. 

Legal and guiding frameworks

Frameworks in the United States of America 

The Pediatric Research Equity Act (2003) requires sponsors to conduct paediatric studies for drugs and biologics likely to be used among children, unless a waiver or deferral is granted. The Best Pharmaceuticals for Children Act, enacted into law in 2002, provides incentives – including six months of additional market exclusivity – for sponsors who voluntarily conduct paediatric studies requested by the United States Food and Drug Administration. Together, these two pieces of legislation have substantially increased the number of paediatric trials conducted and the availability of paediatric labelling information. The United States Food and Drug Administration requires a paediatric study plan and participates in the Paediatric Cluster, a cross-regulator forum for discussing scientific and ethical issues related to paediatric medicinal product development. The Pediatric Review Committee is an internal committee established under the Food and Drug Administration Amendments Act to carry out activities related to the Best Pharmaceuticals for Children Act and Pediatric Research Equity Act, including reviewing and assessing paediatric study plans.

Frameworks in the EU

The Paediatric Regulation (EC No. 1901/2006) established the Paediatric Committee at the EMA and introduced the requirement for a paediatric investigation plan for all new medicines and new indications. A paediatric investigation plan is a development plan that specifies which studies need to involve children to support a paediatric indication, along with agreed timelines and any waivers or deferrals, including if the adult condition does not exist among children. Compliance with an agreed paediatric investigation plan is a prerequisite for marketing authorization in the EU.

Supporting the EU’s regulatory framework, the European Network of Paediatric Research at the EMA brings together research networks, investigators and centres with recognized expertise in paediatric clinical trials. Coordinated by the EMA, the European Network of Paediatric Research strengthens the scientific and ethical foundations of paediatric research by providing a forum for exchange between networks, regulators, industry and academia, building capacity for high-quality studies and contributing to discussing ethical issues in conducting research with children.

WHO

WHO plays a pivotal role in paediatric medicines globally, especially in low- and middle-income countries. The WHO Model List of Essential Medicines for Children and paediatric drug optimi/zation process serve to drive priority-setting and the development of paediatric formulations. In many low- and middle-income countries, national regulatory authorities work alongside WHO and regional bodies such as the African Medicines Agency to implement standards for paediatric clinical trials and access reliance mechanisms. WHO’s Paediatric Regulatory Network provides a platform for exchanging regulatory information on paediatric medical products and to support the availability of quality-assured medical products for children by facilitating communication, collaboration, training and regulatory harmonization across the development, registration, marketing authorization and pharmacovigilance of paediatric medical products.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)

The ICH provides globally harmonized guidelines for paediatric drug development, most notably ICH E11 (Clinical Investigation of Medicinal Products in the Paediatric Population) and its addendum E11(R1), which addresses study design, age groupings, pharmacokinetics and extrapolation from adult data.

Regulatory approval and filing

In most high-income countries, a clinical trial authorization or investigational new drug application must be submitted to the relevant competent regulatory authority before a trial is initiated. For paediatric trials, these applications must include additional information addressing: the scientific justification for studying children in relation to the product; the specific formulation(s) to be used and their age-appropriateness; the dose selection rationale, supported by pharmacokinetic modelling or prior data; the risk minimization measures in place; and the paediatric-specific ethical considerations. Regulatory agencies typically have dedicated paediatric units or committees that review paediatric trial applications.

Box 2. Paediatric investigation plans and paediatric development plans

In the EU, the paediatric investigation plan specifies what studies need to be conducted involving children to support a paediatric indication, the age groups and formulations to be studied and the agreed timelines. Waivers (for products unlikely to benefit children or when studies would be unsafe) and deferrals (allowing adult studies to be completed before paediatric studies begin) can be granted. In other jurisdictions, including the United States of America and many low- and middle-income countries, paediatric development plans or agreed paediatric study plans serve a similar function.

Licensing and marketing

Successfully completing a paediatric development programme and obtaining marketing authorization for a paediatric indication is the ultimate goal of paediatric drug development. In the EU, compliance with an agreed paediatric investigation plan is a prerequisite for marketing authorization; in the United States of America, completing paediatric studies under the Best Pharmaceuticals for Children Act or Pediatric Research Equity Act triggers labelling updates and, for Best Pharmaceuticals for Children Act studies, six months of additional market exclusivity. Even after marketing authorization, post-marketing commitments – including Phase IV studies, pharmacovigilance, and registry enrolment – may be required to  fulfil conditions of approval.


Key resources

Background resources